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ABSTRACT
Introduction: Rheumatoid arthritis (RA) is a
chronic systemic auto-immune disease associ-
ated with a prothrombotic state. Tocilizumab,
an interleukin-6 receptor inhibitor, is highly
effective in controlling disease activity and
thrombotic risk. Factor XIII (FXIII), involved in
thrombotic complications, has been reported to
be reduced in RA patients during maintenance
treatment with tocilizumab, but no data are
available before and after the drug administra-
tion. Thus, we investigated the effects of tocili-
zumab on FXIII, thrombin generation and
inflammation in patients with RA naı¨ve for the
drug.
Methods: We studied 15 consecutive adult
patients with RA at baseline and 4 weeks after
the onset of parenteral administration of toci-
lizumab, measuring disease activity and plasma
levels of C-reactive protein (CRP), FXIII, and
prothrombin fragments F1?2 by immunoenzy-
matic methods. Fifteen healthy subjects, sex-
and age-matched with patients, served as nor-
mal controls for laboratory measurements.
Results: At baseline, patients with established
RA had a median DAS28 of 4.8 (3.2–8.3) and,
compared to healthy controls, had higher
plasma levels of CRP (p\ 0.0001), FXIII
(p = 0.017) and F1?2 (p\ 0.0001). Four weeks
after starting treatment with tocilizumab, based
on the EULAR response criteria, eight patients
were classifiable as responders and seven as non-
responders. In responders, we observed a sta-
tistically significant reduction not only of the
values of DAS28 and CRP (p = 0.012 for both),
ut also of plasma levels of FXIII (p = 0.05) and
F1?2 (p = 0.025). In non-responders, all the
studied parameters were unchanged.
Conclusion: The decrease of FXIII and F1?2
levels after tocilizumab treatment observed only
in those patients who responded to the drug
indicates that the effect of tocilizumab on the
prothrombotic state is linked to the control of
inflammation and disease activity and not to a
direct effect of the drug, thus contributing to
the reduction of the cardiovascular risk.
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Key Summary Points
Why carry out this study?
Rheumatoid arthritis (RA) is a chronic
systemic auto-immune disease associated
with a prothrombotic state whose
pathogenesis is multifactorial and not
completely elucidated.
Factor XIII (FXIII), which is involved not
only in blood coagulation but also in
inflammation and in bone/cartilage
metabolism, has been reported to be
reduced in patients in maintenance
treatment with tocilizumab.
We studied patients with RA naı¨ve for
tocilizumab before and after drug
administration and measured FXIII levels
and the degree of inflammation/disease
activity, and the prothrombin fragment
F1?2, a known marker of prothrombotic
state.
What was learned from the study?
We observed a decrease of FXIII and F1?2
levels after tocilizumab treatment only in
patients who responded to the drug, thus
indicating that the reduction of the
prothrombotic state exerted by
tocilizumab is linked to the regulation of
inflammation and disease activity and not
to a direct effect of the drug.
The decrease of FXIII by tocilizumab may
contribute to the reduction of the
cardiovascular risk that is one of the major
causes of morbidity and mortality in RA
patients.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic
auto-immune disease characterized not only by
joint involvement but also by systemic inflam-
mation, which has been associated with a pro-
thrombotic state responsible for an increased
cardiovascular mortality [1–3].
The control of chronic inflammation by
treatment with disease-modifying anti-rheu-
matic drugs (DMARDs) has been associated with
a reduced cardiovascular risk [4]. Over the last
20 years, the therapeutic management of RA has
been revolutionized by the introduction of
biological DMARDs, which seem more effective
than conventional synthetic DMARDs, not only
in the control of disease but also in reducing
cardiovascular risk [3, 5, 6]. In particular, these
effects seem to be major with tocilizumab—a
human monoclonal antibody directed against
interleukin-6 (IL-6) receptor—than with inhibi-
tors of tumor necrosis factor (TNF) [7, 8]. Fur-
thermore, tocilizumab has been reported to
reduce plasma levels of factor XIII (FXIII) [9–11].
FXIII is a tetrameric zymogen consisting of two
potentially active subunits A (FXIIIA) and two
inhibitory/carrier subunits B (FXIIIB). It is acti-
vated by the concerted action of thrombin and
Ca2? in the terminal phase of the clotting
cascade. After cleavage by thrombin in the
presence of Ca2? , FXIIIB dissociates, and the
FXIIIA dimer becomes active. Activated FXIII is
a transglutaminase that is able to cross-link the
c- and a-chains of fibrin, thus leading to the
stabilization of fibrin clots, which become more
resistant to fibrinolysis [12]. The important
involvement of FXIII in the coagulation cascade
is supported by the evidence that FXIII defi-
ciency is associated with a bleeding syndrome,
whereas an excess of FXIII has been associated
with thrombosis [13, 14]. Finally, evidence in
experimental models of RA supports the
involvement of FXIII in cartilage and bone
destruction [15, 16], showing that the reduction
of FXIII activity leads to improvement of carti-
lage and bone lesions [15].
To the best of our knowledge, no evidence of
the effect of tocilizumab on FXIII levels is cur-
rently available in patients with active RA naı¨ve
to this treatment. Therefore, the aim of our
study was to investigate the effect of tocilizu-
mab on FXIII in such patients and to evaluate
its correlation with clinical response, pro-
thrombotic parameters and inflammation.
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METHODS
Patient Population
We studied 15 consecutive adult patients with
RA (13 women and 2 men), median age 57 years
(min 30–max 72 years) attending the out-pa-
tient clinic of Gaetano Pini Institute in Milan,
Italy, from July 2017 to January 2019, and ful-
filling 2010 American College of Rheumatology
(ACR) criteria for RA [17], naı¨ve for tocilizumab.
Demographic and clinical characteristics of the
study population are reported in Table 1.
Patients treated with oral anticoagulants and
patients with other diseases of coagulation were
excluded. The sample size was calculated in
order to obtain a statistical power of 80%, with
an alpha error of 5%, based on the study by
Mokuda et al., which showed a 40% decrease in
FXIII levels in patients treated with tocilizumab
compared to normal subjects [10]. Furthermore,
the sample size was confirmed based on our
previous study, showing a decrease of F1?2
levels of around 60% in patients treated with
tocilizumab compared with baseline levels [8].
At baseline and 4 weeks after the onset of
subcutaneous administration of tocilizumab
(162 mg weekly), disease activity was measured
and blood samples were collected for measure-
ment of C-reactive protein (CRP), FXIII, and
prothrombin fragments F1?2. For the same
parameters, 15 healthy subjects sex- and age-
matched with patients served as normal con-
trols. The control group consisted of 13 women
and 2 males, median age 55 years (min 28–max
73 years); a smoking habit was reported by one
subject.
The authors received Ethics Committee
approval on 20 July 2017 (Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico di
Milano, no. 484_2017). The study conformed
with the Helsinki Declaration of 1964, as revised
in 2013, concerning human and animal rights,
and Springer’s policy concerning informed
consent has been followed.
Disease Activity Assessment
Disease activity was measured based on the
evaluation of 28 joints and erythrocyte sedi-
mentation rate (DAS28) [18]. Response to toci-
lizumab was assessed on the basis of the
European League Against Rheumatism (EULAR)
response criteria [19], in particular, good
Table 1 Demographic and clinical characteristics of the study population
Total RA patients (n) 15
Median age (min–max) 57 (30–72) years
Median disease duration (min–max) 10.7 (1.5–35.1) years
Females % (n) 86.7% (13)
Smoking habit % (n) 13.3% (2)
RF positivity % (n) 60% (9)
ACPA positivity % (n) 66.7% (10)
Daily equivalent prednisone dose C 5 mg/day % (n) 73.3% (11)
Mean prednisone daily dose 4.5 mg
Weekly MTX dose C 10 mg/week % (n) 33.3% (5)
Mean MTX weekly dose 12 mg
Median number of previous biologic drugs (min–max) 2 (0–6)
RA rheumatoid arthritis, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, MTX methotrexate
3496 Adv Ther (2019) 36:3494–3502
responders were considered patients with
DAS28 scores of 3.2 or less with reductions in
DAS28 of more than 1.2. Patients with DAS28
scores over 3.2 who have reductions in DAS28
scores of more than 1.2 have moderate respon-
ses. Patients with reductions in DAS28 of less
than 0.6 are non-responders.
Plasma Measurement
CRP was measured with a sandwich enzyme-
linked immunosorbent assay (ELISA; Zymutest
CRP; Hyphen BioMed, Neuville-sur-Oise,
France). Intra- and inter-assay coefficients of
variation (CV) were lower than 11%.
FXIII levels were measured in plasma sam-
ples by means of an ELISA (HemosIL Factor XIII
Antigen; Instrumentation Laboratory, Bedford,
MA, USA) is expressed as the % of normal. The
method is highly specific for the potentially
active subunit A of FXIII. The intra- and inter-
assay CV is lower than 8.1%.
Prothrombin fragment F1?2 levels were
measured in plasma using an ELISA (Enzygnost
F1?2; Siemens Healthcare Diagnostics, Mar-
burg, Germany), with intra- and inter-assay CVs
of 5% and 8%, respectively.
Statistical Analysis
Since the data were positively skewed and the
test of Kolmogorov–Smirnov excluded a normal
distribution, we have reported the results as
median (minimum–maximum) values. The
Mann–Whitney U test was used to compare
different groups (healthy vs. RA) and Wilcoxon
test for paired samples to compare the baseline
with 4-week values in RA patients. Correlations
were calculated by means of Spearman’s rho.
Significance level was set at p\ 0.05. Data were
analyzed using the SPSS PC statistical package
v.25.0 (IBM, Armonk, NY, USA).
RESULTS
At baseline, patients with RA compared with
healthy controls had significantly higher med-
ian plasma levels of CRP: 8.9 lg/mL
(0.1–17.9 lg/mL) versus 0.9 lg/mL (0.2–4.1 lg/
mL, p\ 0.0001); FXIII: 146% (81-197) versus
105% (74–139, p = 0.017); F1?2: 342 pmol/mL
(211–1483 pmol/mL) vversus 180 pmol/mL
(116–283 pmol/mL, p\0.0001). DAS28 median
levels were 4.8 (3.2–8.3).
After 4 weeks from the onset of tocilizumab
treatment, 8 patients were responders, accord-
ing to the EULAR response criteria [19], and 7
patients were non-responders. At baseline, there
were no differences between responders and
non-responders in terms of DAS28, CRP, FXIII
and F1?2. None of the patients experienced
bleeding complications. No changes in medi-
cations were reported during the study period.
As expected, in responders, we observed a
significant decrease of median DAS28 and of
CRP plasma levels (p = 0.012 for both; Fig. 1;
Table 2). Furthermore, we observed a reduction
of median plasma levels of FXIII (p = 0.05;
Fig. 2; Table 2) and of F1?2 (p = 0.025; Fig. 3;
Table 2). In non-responders, all these parame-
ters were not significantly different after
4 weeks compared to baseline (Figs. 1, 2, 3;
Table 2).
Then, we sought to find correlations between
the different clinical and laboratory parameters
and found significant correlations between
DAS28 and CRP levels (r = 0.63, p = 0.01) as
expected, between CRP and F1?2 levels
(r = 0.57, p = 0.001) and between FXIII and
F1?2 levels (r = 0.46, p = 0.01), supporting the
strict relationship between the activity of the
disease and the prothrombotic parameters.
DISCUSSION
To the best of our knowledge, this is the first
study showing that tocilizumab reduces the
levels of the prothrombotic biomarker F1?2
and FXIII subunit A, which in RA patients with
active disease are higher than in healthy con-
trols. This effect is already observed after
4 weeks in patients who clinically respond to
the drug. Thus, our data indicate that IL-6 sig-
naling blockade by tocilizumab may reduce the
prothrombotic state that is well known in RA, as
shown by a number of studies from several
authors and from our group [3, 5, 6, 8, 20].
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As far as we know, to date, higher levels of
FXIII during the acute phase of RA have never
been reported, and we did not find any study in
the literature describing FXIII as an acute phase
reactant. Indeed, in our active RA patients, the
levels of FXIII before the administration of
tocilizumab were significantly higher than in
normal controls. High FXIII levels have been
demonstrated to be associated with cardiovas-
cular diseases, such as myocardial infarction
and obliterative atherosclerosis of the lower
limb, as well as with diabetes [21–26], whereas
lower FXIII levels, such as those observed in
patients with some polymorphisms in their
FXIII genes, decrease the risk of coronary artery
disease [21, 22, 27]. Therefore, the lowering
effect of tocilizumab on FXIII levels may be a
further mechanism of reduction of the cardio-
vascular risk. It is well known that the congen-
ital FXIII deficiency is associated with a
hemorrhagic syndrome characterized by
impaired wound healing, recurrent miscar-
riages, bleeding of soft tissues, and life-threat-
ening central nervous system bleeding, for
which a replacement therapy is currently
available [28]. The acquired FXIII deficiency,
Fig. 1 Plasma levels of C-reactive protein (CRP) in
rheumatoid arthritis patients treated with tocilizumab
(TCZ) at baseline and after 4 weeks, divided based on
the EULAR response criteria. Responders showed a
significant reduction of CRP plasma levels, whereas in
non-responders the levels were not significantly (ns)
different. The dashed line represents the median value of
normal subjects
Table 2 Disease activity (DAS28) and plasma levels of C-reactive protein (CRP), factor XIII (FXIII) and prothrombin
fragment F1?2 in 15 patients with rheumatoid arthritis treated with tocilizumab at baseline and after 4 weeks, divided
based on the EULAR response criteria
Healthy controls Responders Non-responders
Baseline After 4 weeks Baseline After 4 weeks
DAS28 – 5.1 (3.2–6.3) 1.8 (0.9–2.9)*** 4.4 (3.5–8.3) 4.3 (3.4–7.5)
CRP lg/ml 0.9 (0.2–4.1) 12.9 (4.5–17.2) 0.5 (0.1–3.5)*** 4.5 (0.1–17.9) 8.0 (0.2–15.8)
FXIII % 105 (74–139) 131 (95–166) 112 (93–133)* 148 (81–197) 156 (90–190)
F1?2 pmol/ml 180 (116–283) 354 (317–1483) 330 (146–536)** 278 (211–751) 277 (181–396)
Values are expressed as median with minimum and maximum in parentheses
Statistical significance: ***p = 0.012; **p = 0.025; *p = 0.05
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which is due to the production of auto-anti-
bodies in the course of several conditions, such
as auto-immune diseases or malignancy, is an
emerging disorder [29]. An acquired FXIII defi-
ciency not due to auto-antibody production has
also been reported in a few Japanese patients
with RA treated with tocilizumab [9, 11], but, to
the best of our knowledge, it has never been
reported in Caucasian patients.
Besides its role in the final stage of the
coagulation cascade, FXIII has been shown to
have several other biological functions. In par-
ticular, it is involved in cartilage and bone
metabolism and inflammation, as demon-
strated by experimental studies in which
reducing FXIII levels provide protection from
inflammation and bone erosions in an induced
arthritis model in mice [15]. Intriguingly, in an
Fig. 2 Plasma levels of factor XIII (FXIII) in rheumatoid
arthritis patients treated with tocilizumab (TCZ) at
baseline and after 4 weeks, divided based on the EULAR
response criteria. Responders showed a significant
reduction of FXIII plasma levels, whereas in non-respon-
ders the levels were not significantly (ns) different. The
dashed line represents the median value of normal subjects
Fig. 3 Plasma levels of prothrombin fragment F1?2 in
rheumatoid arthritis patients treated with tocilizumab
(TCZ) at baseline and after 4 weeks, divided based on the
EULAR response criteria. Responders showed a significant
reduction of F1?2 plasma levels, whereas in non-respon-
ders the levels were not significantly (ns) different. The
dashed line represents the median value of normal subjects
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observational study in patients with RA treated
with tocilizumab monotherapy, a consistent
improvement of existing bone erosions has
been demonstrated [30]. The mechanism
underlying the reduction of FXIII induced by
tocilizumab is presently unknown. However, as
the production of FXIII from monocytes of the
synovial membrane of RA patients is high [31],
one can expect that the reduction of the
inflammatory stimulation on the synovial
membrane may play a role in decreasing the
production and release of FXIII. Indeed,
Mokuda et al. also found reduced FXIII levels in
patients treated with TNF inhibitors, but this
reduction did not reach the magnitude
observed with tocilizumab [10].
F1?2 plasma levels were already reduced
4 weeks after the drug administration in the
group of responders, but not in the group of
non-responders (Fig. 3). This observation sup-
ports the view that tocilizumab is able to reduce
the prothrombotic state of RA only if a reduc-
tion of inflammation and of disease activity is
obtained. The procoagulant state of RA patients
revealed by the high plasma levels of F1?2 is
considered the effect of proinflammatory
cytokines, which can be counteracted by IL-6
blockade and was also observed after TNF inhi-
bition [5, 8]. Accordingly, we observed a posi-
tive correlation between markers of
prothrombotic state and inflammation. Actu-
ally, the levels of CRP, a reliable marker of
inflammation, were not decreased in a relatively
high number of patients (6 out of 15) 4 weeks
after tocilizumab use. However, these data are
in agreement with those reported by other
authors, such as Wang et al. [32] and Gabay
et al. [33], the latter reporting a response rate to
tocilizumab of 40% (DAS28 remission).
The main limitation of our study is the small
number of patients, which was due to the dif-
ficulty in finding patients starting a new treat-
ment with tocilizumab after an appropriate
washout from other biological therapies. How-
ever, this sample size allowed us to obtain a
statistical power of 80%, with an alpha error of
5%, and to gather a sample of patients with
active disease, naı¨ve for tocilizumab treatment.
Indeed, Mokuda et al. stated that RA patients
treated with tocilizumab had lower levels of
FXIII than normal controls, but they were in
maintenance treatment and had low DAS28
values [10]. In contrast, our patients before the
administration of tocilizumab were experienc-
ing an acute phase of the disease with high
DAS28 values and CRP plasma levels.
Another limitation was the short time of
follow-up (4 weeks); therefore, we cannot
exclude that a longer period of treatment may
lead to a different response rate and prothrom-
botic state.
A peculiarity of our study is that we were able
to compare a group of patients responding to
the drug with a group of patients not respond-
ing to the drug. The observation that only
responders to the drug had a reduction of FXIII
and F1?2 suggests that the reduction of the
prothrombotic state exerted by tocilizumab is
linked to the regulation of inflammation and
disease activity and not to a direct effect of the
drug.
CONCLUSIONS
In RA patients, we observed a decrease of FXIII
and F1?2 levels after tocilizumab treatment
only in those patients who responded to the
drug. This may indicate that the effect of toci-
lizumab on the prothrombotic state is due to
the control of inflammation and disease activity
and not to a direct action of the drug. The effect
of tocilizumab on FXIII may be a further
mechanism contributing to the reduction of the
cardiovascular risk that is one of the major
causes of morbidity and mortality in RA
patients.
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